Home Page
Welcome to the Canadian Hereditary Angioedema Network (CHAEN)/ Rèseau Canadien d'Angioédème Héréditaire (RCAH) site.
This site is dedicated to:
- Educating to increase awareness of issues affecting care and treatment.
- Encouraging peer support and information sharing of persons with an interest in HAE.
- Encouraging research that will continue to improve care and result in a cure for HAE.
News
July 2010- The 2010 Canadian HAE management consensus article and the 2010 international consensus algorithm for diagnosis, therapy and mangementof HAE articles have been published. See this link for more details.
- CSL Behring Canada announced today that it has received Notice of Compliance for Berinert (Human C1 Esterase Inhibitor). Berinert may now be marked in Canada for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) of moderate and severe intensity. From www.cslbehring.com.
- There was a general meeting of the Canadian Hereditary Angioedema Network (CHAEN) / Rèseau Canadien d'Angioédème Héréditaire (RCAH) May 14-16, 2010 in Toronto. This meeting featured presentations from Canadian and international health professionals concerning the diagnosis, therapy, and management of HAE. The major goal of this meeting was to update the Canadian Consensus approach to HAE. See the agenda and resulting Canadian and International consensus articles.
Disclaimer
The information, including opinions and recommendations, contained in this website is for educational purposes only. Such information is not intended to be a substitute for professional medical advice, diagnosis or treatment. No one should act upon any information provided in this website without first seeking medical advice from a qualified medical physician. Information derived from the internet or emails, no matter how accurate or relevant is no substitute for competent medical care.
Document Created: 2006/07/10
Last Modified: 2010/08/02